The clinical sensitivity of a single SARS-CoV-2 upper respiratory tract RT-PCR test for diagnosing COVID-19 using convalescent antibody as a comparator

Authors: Abigail Holborow, Hiho Asad, Lavinia Porter, Poppy Tidswell, Claire Johnston, Ian Blyth, Alice Bone and Brendan Healy

ABSTRACT

The clinical false negative rate of reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 on a single upper respiratory tract sample was calculated using convalescent antibody testing as a comparator. The sensitivity in symptomatic individuals was 86.2% (25/29). Of the missed cases, one (3.5%) was detected by repeat RT-PCR, one by CT thorax and two (7.1%) by convalescent antibody. The clinical false negative rate of a single RT-PCR on an upper respiratory tract sample of 14% in symptomatic patients is reassuring when compared to early reports. This report supports a strategy of combining repeat swabbing, use of acute and convalescent antibody testing and CT thorax for COVID-19 diagnosis.

KEYWORDS: COVID-19, SARS-CoV-2 RT-PCR, clinical sensitivity, COVID-19 antibody

DOI: 10.7861/clinmed.2020-0555

Introduction

The clinical sensitivity of reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 on a single upper respiratory tract specimen is a source of ongoing debate, partly fuelled by early reports of low sensitivity of throat swabs. While RT-PCR is highly specific and remains the principal method for detecting COVID-19 infection across the world, understanding the false negative rate is important so that clinicians have an estimate of the reliability of the test when making management plans based on the results.

Methods

Results from two clusters of infection among healthcare workers in well-defined settings were analysed using RT-PCR and convalescent antibody testing. Staff that were RT-PCR-negative were tested for antibody using EUROIMMUN Anti-SARS-CoV-2 ELISA assay for detection of IgG antibodies 6–8 weeks after the cluster of infection. The clinical false negative rate was calculated by comparing the results from a single RT-PCR swab with results from repeat swabs (where taken), CT chest (where available and strongly suggestive of COVID-19) and convalescent antibody testing. The data presented here were collected as part of routine service. The paper has been reviewed by local information governance and ethics committees and deemed suitable for publication.

Results

127 staff were working in the defined areas and had potential exposure during the outbreak period. 42 were symptomatic, of whom 25 were positive following a single swab. Six of the negative-swab individuals underwent a second swab, of whom five were negative and one was positive (repeat swab 13 days after initial swab but no new symptoms in between). 13 out of 16 staff with...
negative RT-PCR tests underwent convalescent antibody testing and the result was positive in two and negative in 10. One of the individuals who was negative by RT-PCR but did not have convalescent antibody testing had a CT chest that was highly suggestive of COVID-19; this was considered a false negative RT-PCR result for analysis. Overall, 29 symptomatic individuals were considered positive (25 first RT-PCR positive, one second RT-PCR positive, one CT positive, two convalescent antibody positive). The clinical false negative rate of a single throat swab was 14% (4/29). There were no convalescent antibody data on three individuals.

Eighty-five individuals were asymptomatic; 73 were swabbed, 10 were tested positive for antibody. +ve = detected; –ve = not detected; NP = not performed.

Table 1. Number of individuals from cluster investigation broken down by symptoms, RT-PCR results and convalescent SARS-CoV-2 antibody/CT thorax findings consistent with COVID-19

<table>
<thead>
<tr>
<th></th>
<th>Symptomatic, n=42</th>
<th>Asymptomatic, n=85</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>+ve</td>
<td>–ve</td>
</tr>
<tr>
<td>First RT-PCR</td>
<td>25</td>
<td>17</td>
</tr>
<tr>
<td>Second RT-PCR</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Antibody</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>CT</td>
<td>1*</td>
<td>NA</td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
<td>NA</td>
</tr>
</tbody>
</table>

* Subsequent to original submission this individual has also now tested positive for antibody. +ve = detected; –ve = not detected; NP = not performed.

Discussion

The presentation of COVID-19 is varied and non-uniform, ranging from asymptomatic infection and mild disease through to severe infection and death. The varied presentation and the overlap of symptoms and signs with other viral illnesses, respiratory and infection syndromes means that the clinical presentation alone cannot be relied upon for diagnosis.

None of the currently available tests are 100% sensitive or specific, resulting in an element of uncertainty when managing cases. An estimate of the clinical false negative rate is useful when managing this uncertainty given the potential implications associated with a missed diagnosis.

Concerns about the clinical sensitivity of the RT-PCR test have been fuelled by reports suggesting a high clinical false negative rate, with a sensitivity ranging from 32–70% for a single pharyngeal sample. The sensitivity of a single RT-PCR test will vary according to the disease stage (increased chance of positivity early in the illness), the site of infection (the virus may be differentially expressed at different sites during the course of the illness), the quality of the sampling, the analytical sensitivity of the assay and perhaps the severity of the infection. The sensitivity of RT-PCR of 86% is in keeping with other published studies. It is at the upper end. We believe that it is likely that some studies that have quoted a sensitivity at the lower end (eg 30%) likely underestimate the sensitivity of RT-PCR testing in the UK through a combination of factors including incorrect

Table 2. Sensitivity of single SARS-CoV-2 RT-PCR test on healthcare staff individuals during two clusters of infection

<table>
<thead>
<tr>
<th></th>
<th>Symptomatic</th>
<th>Asymptomatic</th>
<th>Combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cluster 1</td>
<td>87.50%</td>
<td>60%</td>
<td>77%</td>
</tr>
<tr>
<td>Cluster 2</td>
<td>85%</td>
<td>80%</td>
<td>83%</td>
</tr>
<tr>
<td>Total</td>
<td>86%</td>
<td>67%</td>
<td>80%</td>
</tr>
</tbody>
</table>

Subsequently CT thorax has been proposed as a diagnostic tool. CT scans are sensitive but lack specificity. Individuals will present for diagnosis at different stages of infection. Key workers seeking a diagnosis from an occupational health perspective and those tested during contact tracing will mostly present in the early phases of the illness. Those presenting to hospital can present at potentially any time point in the illness. Individuals may present in the early stages when the infection has caused some form of decompensation requiring hospital care (for example, a fall in the elderly or hyperglycaemia in diabetics). Others will present later during the respiratory phase of the illness. The sensitivity and specificity of RT-PCR, radiographic examinations and antibody tests vary according to the stage of the disease in a complementary fashion.

Antibody tests have a sensitivity and specificity in the region of 90–100%. The Euroimmun assay used in this study has a specificity of 95–100% and a sensitivity (which increases with time since onset of infection) of 90%. The specificity of antibody testing has been determined by detecting antibody in individuals who were positive by RT-PCR. Convalescent antibody testing facilitates retrospective diagnosis of cases that might not be detected by RT-PCR because of the timing of the sample (eg early or late on in the disease process). However, it is possible that some true cases of COVID-19 will be negative by both RT-PCR and antibody testing.

This study demonstrates that the clinical false negative rate for SARS-CoV-2 RT-PCR in symptomatic individuals in a UK setting is around 14% (Table 2). The strength of this study is the use of a combination of very sensitive and specific tests (antibody, repeat RT-PCR and high likelihood CT) to determine the true clinical false negative result of RT-PCR. The sensitivity and specificity of a combined diagnostic approach of RT-PCR plus acute and convalescent antibody plus CT scan or chest X-ray (when appropriate) is not known but is likely to be high. Each modality complements the other, as each has a maximum sensitivity at different stages of the disease.

Limitations of the study include the lack of acute serum and the time (6–8 weeks) that elapsed from the outbreak to the convalescent antibody testing. As such, it is possible that some individuals developed infection at another time that was not related to the outbreak. This is particularly relevant in the asymptomatic group, where the high false negative RT-PCR rate may be partly explained by acquisition of infection remote from the outbreak. Others may have had mild infection and either not mounted a significant enough antibody response to be picked up or had a weak antibody response that had waned by the time of testing.

Subsequent to original submission this individual has also now tested positive for antibody. +ve = detected; –ve = not detected; NP = not performed.
diagnosis of COVID-19 in individuals with other infections and issues related to sampling and RT-PCR testing.

Conclusion
In summary we have demonstrated that in a UK centre the clinical sensitivity of a single RT-PCR on an upper respiratory tract sample is 86% when compared to repeat swab results, highly suggestive CT scan results (where available) and convalescent antibody testing in symptomatic individuals.

We suggest that patients with negative RT-PCR samples should be clinically re-evaluated and carefully assessed. Decisions in relation to clinical management and placement should be based on that assessment, taking into account the presenting symptoms and results from blood tests (including acute and convalescent antibody testing) and imaging.

Consideration should be given to re-swabbing, testing lower respiratory tract samples (where appropriate) and using acute and convalescent antibody testing and CT thorax and/or chest X-ray where appropriate to aid the diagnostic process, including retrospective diagnosis that may be useful to guide follow-up. Interpretation of all results should also take into consideration the stage of the disease based on the days that have elapsed since symptom onset.

Acknowledgments
We would like to thank Shelley Evans for her support in collating some of the data.

References

Address for correspondence: Dr Brendan Healy, Public Health Wales Microbiology Department, 8 Eaton Cres, Sketty, Swansea SA2 8QA, UK.
Email: brendan.healy@wales.nhs.uk